Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Change in Accured Expenses (2018 - 2025)

Dna X (SONM) has disclosed Change in Accured Expenses for 8 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 85.59% year-over-year to $1.4 million, compared with a TTM value of -$2.9 million through Sep 2025, down 122.94%, and an annual FY2024 reading of $8.0 million, up 487.88% over the prior year.
  • Change in Accured Expenses was $1.4 million for Q3 2025 at Dna X, up from -$1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $9.8 million in Q3 2024 and bottomed at -$2.9 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is $467578.9, with a median of $315000.0 recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 1886.42% in 2023, while the deepest fall reached 778.1% in 2023.
  • Year by year, Change in Accured Expenses stood at -$331000.0 in 2021, then soared by 124.47% to $81000.0 in 2022, then soared by 1886.42% to $1.6 million in 2023, then plummeted by 275.7% to -$2.8 million in 2024, then surged by 149.77% to $1.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for SONM at $1.4 million in Q3 2025, -$1.2 million in Q2 2025, and -$218000.0 in Q1 2025.